NSABPB35_2 | R Documentation |
Kaplan-Meier digitized data from NSABPB35, figure 2 (PMID 26686957). A reported sample size of 3,104 for a primary endpoint of BCFS in breast cancer.
NSABPB35_2
A data frame of 3,077 observations and 3 variables:
time | event time (in months) | |
event | EFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (anastrazole, tamoxifen) | |
Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 2016; 387: 849–56.
summary(NSABPB35_2)
kmplot(NSABPB35_2)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.